ReceptorPAINT
Financiado
Imaging Receptomics as a tool for biomedical discovery
Targeting cell surface proteins to alter cellular behavior is a major aim of many therapeutics. Recently approved immunotherapeutic drugs trigger anti-tumor immunity by disrupting key cell surface proteins that guide immune cell i...
Targeting cell surface proteins to alter cellular behavior is a major aim of many therapeutics. Recently approved immunotherapeutic drugs trigger anti-tumor immunity by disrupting key cell surface proteins that guide immune cell interactions. Despite the cell surface representing a major site of drug action, its nanoscale organization remains poorly characterized. The main reason for this is largely due to technical limitations of current fluorescence and super-resolution imaging approaches, which do not allow high-throughput measurements of the spatial localization and interaction of hundreds of proteins with true single-protein- resolution on cell surfaces. We here propose to develop exactly such a disruptive capability by advancing recently developed DNA-PAINT microscopy to enable the visualization and quantification of all relevant cell surface proteins at single-protein-resolution. We will achieve this by innovating DNA-PAINT to enable isotropic 1-nm-resolution, develop DNA-based protein binders against all cell surface proteins, and devise multiplexing capabilities to resolve them with single-protein-resolution over large fields of view, reaching the ultimate goal of enabling Imaging Receptomics. We will then apply this to test the central hypothesis that surface protein architecture and patterning on immune and tumor cells dictates the outcome of their interactions. We will map the nanoscale organization of hundreds of key immunomodulatory surface proteins and their corresponding ligands on key interacting pairs of immune cells relevant to current immunotherapy approaches (dendritic cells and T cells), as well as tumor cells. This will yield fundamental insights into the molecular architecture of their interactions and potentially enable the future development of more refined pattern-based immunotherapeutics. Collectively, this highly multidisciplinary and novel approach has the potential to be ground-breaking across a range of research fields.
ver más
Duración del proyecto: 71 meses
Fecha Inicio: 2021-04-30
Fecha Fin: 2027-03-31
Fecha Fin: 2027-03-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-04-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-COG:
ERC CONSOLIDATOR GRANTS
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
361.93K€ |
Participante